HONG KONG – Shanghai-based Cellular Biomedicine Group Inc. (CBMG), having gotten its start in autologous stem cells has strengthened its position in another area of regenerative cellular therapy, cancer immuno-oncology, with the acquisition of chimeric antigen receptor T-cell (CAR T) technology and data from the People's Liberation Army General Hospital (PLAGH) in Beijing.